MEDICON a.s.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
MEDICON a.s. is conducting studies that target atherosclerotic cardiovascular disease, heart failure with preserved or mildly reduced ejection fraction, and related metabolic conditions. The trials aim to test new oral agents and anti‑inflammatory antibodies for reducing major cardiovascular events and improving heart‑failure symptoms.
- Oral glucagon‑like peptide‑1 receptor agonist compared with insulin for cardiovascular risk reduction
- Anti‑inflammatory monoclonal antibody versus placebo in heart‑failure patients
- Combination therapy to lower MACE in participants with ASCVD, chronic kidney disease and systemic inflammation
- Weight‑management compound evaluated for impact on cardiovascular outcomes
Across the site, eight investigators are involved in eleven active cardiovascular trials, reflecting a strong focus on innovative heart‑health solutions.
Musculoskeletal Diseases
Research at the department includes a study on chronic non‑specific low back pain where standard non‑opioid analgesics have proven insufficient. The goal is to determine the optimal dose of a novel oral analgesic for pain relief and functional improvement.
- Dose‑response characterization of a new analgesic for chronic low back pain
- Evaluation of pain reduction when previous non‑opioid treatments fail
The musculoskeletal program leverages the expertise of several investigators to address unmet needs in pain management.
Nutritional and Metabolic Diseases
The site’s metabolic portfolio focuses on obesity, overweight, and type 2 diabetes. Trials assess innovative oral compounds and weekly injectable peptides designed to enhance weight loss, improve glycemic control, and lower cardiovascular and renal complications.
- Oral agent versus insulin glargine for patients with type 2 diabetes and obesity
- Weekly peptide evaluated for cardiovascular and kidney outcomes in obesity
- Investigational molecule for weight management in overweight individuals without diabetes
With a total of eleven active studies, the metabolic research team is advancing therapies that target both weight reduction and disease‑related risk factors.
Respiratory Tract Diseases
Clinical work at MEDICON a.s. includes several investigations into chronic obstructive pulmonary disease (COPD) and asthma. The objectives range from improving inhaler safety to adding novel anti‑inflammatory agents to existing triple‑therapy regimens, with the aim of reducing exacerbations and enhancing lung function.
- Triple inhaled therapy versus dual bronchodilator for severe cardiopulmonary outcomes in COPD
- Safety comparison of a new propellant formulation for an asthma metered‑dose inhaler
- Add‑on inhaled drug to reduce moderate and severe COPD exacerbations
- Evaluation of a novel agent for improved COPD control
The respiratory program involves eight investigators and contributes to a broader effort to advance treatment options for chronic lung diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MEDICON a.s.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study of Subcutaneous PF‑07275315 in Adults with Moderate‑to‑Severe Chronic Obstructive Pulmonary Disease | Pfizer Inc. | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 2 | Unknown | 2021-05-11 | 2023-07-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.